Michael L. Jackson’s research focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal investigator for the United States Influenza Vaccine Effectiveness Network. This Network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this Network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies. He also uses mathematical models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenza type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with GHRI from 2002 to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to GHRI as an assistant investigator in 2010.
Disease burden, risk factors, transmission dynamics, surveillance and response
Rates of adverse events, safety of new vaccines
Methodology, removing bias in effectiveness estimates
Texier G, Farouh M, Pellegrin L, Jackson ML, Meynard JB, Deparis X, Chaudet H. Outbreak definition by change point analysis: a tool for public health decision? BMC Med Inform Decis Mak. 2016 Mar 12;16(1):33. doi: 10.1186/s12911-016-0271-x. PubMed
Glanz JM, Newcomer SR, Jackson ML, Omer SB, Bednarczyk RA, Shoup JA, DeStefano F, Daley MF. White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine. 2016;34 Suppl 1:A1-A29. doi: 10.1016/j.vaccine.2015.10.082. PubMed
Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham C, Naleway AL, Lee GM, Hambidge S, Jackson ML, Omer SB, McCarthy N, Nordin JD. Maternal Tdap vaccination: coverage and acute safety outcomes in the Vaccine Safety Datalink, 2007-2013. Vaccine. 2016 Jan 4. pii: S0264-410X(15)01843-5. doi: 10.1016/j.vaccine.2015.12.046. [Epub ahead of print].
Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B. Influenza vaccine effectiveness against the 2009 pandemic A (H1N1) virus differed by vaccine type during 2013-14 in the United States. J Infect Dis. 2016 Jan 6. pii: jiv577. [Epub ahead of print]. PubMed
A GHRI pilot study shows that a self-swab test may help individual patients and whole populations.
KPLU, January 15, 2015